Current Practices for U.S. Newborn Screening of Pompe Disease and MPSI
Open Access
- 2 September 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 6 (3), 72
- https://doi.org/10.3390/ijns6030072
Abstract
Two lysosomal storage disorders (LSDs), Pompe disease and Mucopolysaccharidosis type I (MPSI) were added to the Recommended Uniform Screening Panel (RUSP) for newborn screening (NBS) in 2015 and 2016, respectively. These conditions are being screened with variable practice in terms of primary and reflex analytes (either biochemical or molecular testing) as well as collection of short- and long-term follow-up elements. The goal of this study is to evaluate practices of state health departments in regards to screening methods and follow-up data collected. We conducted online surveys and phone questionnaires to determine each U.S. state’s practices for screening and follow-up of positive newborn screens. We report the first snapshot of practices for NBS for the LSDs included on the RUSP. All 50 U.S. states responded to our survey. The majority of U.S. states are not currently screening for Pompe disease and MPSI as of March 2020, but this number will increase to 38 states in the coming 1–3 years based on survey results. Our survey identifies data elements used by state health departments for short-and long-term follow-up that could serve as the basis of common elements for larger, public health-based analyses of the benefits and efficacy of screening for Pompe disease and MPSI.Keywords
This publication has 33 references indexed in Scilit:
- Heparan sulfate and dermatan sulfate derived disaccharides are sensitive markers for newborn screening for mucopolysaccharidoses types I, II and IIIMolecular Genetics and Metabolism, 2012
- Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare diseaseOrphanet Journal of Rare Diseases, 2011
- False Positive Newborn Screening Results Are Not Always BenignPublic Health Genomics, 2010
- Long-term follow-up of newborn screening patientsGenetics in Medicine, 2010
- The inborn errors of metabolism information system: A project of the Region 4 Genetics Collaborative Priority 2 WorkgroupGenetics in Medicine, 2010
- Determination of Total Homocysteine, Methylmalonic Acid, and 2-Methylcitric Acid in Dried Blood Spots by Tandem Mass SpectrometryClinical Chemistry, 2010
- Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot programMolecular Genetics and Metabolism, 2010
- Reduction of the false‐positive rate in newborn screening by implementation of MS/MS‐based second‐tier tests: The Mayo Clinic experience (2004–2007)Journal of Inherited Metabolic Disease, 2007
- Recombinant human acid α-glucosidaseNeurology, 2007
- Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental StressJAMA, 2003